To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.

Conditions:   Myelodysplastic Syndromes;   Multiple Myeloma;   Anemia Intervention:   Drug: INCB000928 Sponsor:   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Clin Lymphoma Myeloma Leuk. 2021 Aug 2:S2152-2650(21)00315-3. doi: 10.1016/j.clml.2021.07.031. Online ahead of print.ABSTRACTMyelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supple...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
ObjectiveSomatic mutations inUBA1 cause a newly defined syndrome known as VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome). More than 50% of patients currently identified as having VEXAS met diagnostic criteria for relapsing polychondritis (RP), but clinical features that characterize VEXAS within a cohort of patients with RP have not been defined. We undertook this study to define the prevalence of somatic mutations inUBA1 in patients with RP and to create an algorithm to identify patients with genetically confirmed VEXAS among those with RP.MethodsExome and targeted sequencing ofUBA1 was performe...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
AbstractObjectiveSomatic mutations in ubiquitin activating enzyme 1 (UBA1) cause a newly defined syndrome known as VEXAS. More than fifty percent of patients currently identified with VEXAS meet diagnostic criteria for relapsing polychondritis (RP). Clinical features that characterize VEXAS within a cohort of RP have not been defined.MethodsExome and targeted sequencing of theUBA1 gene was performed in a prospective observational cohort of patients with RP. Clinical and immunological characteristics of patients with RP were compared based on presence or absence ofUBA1 mutations. Random forest was used to derive a clinical ...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: ORIGINAL ARTICLE Source Type: research
tizzo Autoimmune cytopenias (AICy) and autoimmune diseases (AID) can complicate both lymphoid and myeloid neoplasms, and often represent a diagnostic and therapeutic challenge. While autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) are well known, other rarer AICy (autoimmune neutropenia, aplastic anemia, and pure red cell aplasia) and AID (systemic lupus erythematosus, rheumatoid arthritis, vasculitis, thyroiditis, and others) are poorly recognized. This review analyses the available literature of the last 30 years regarding the occurrence of AICy/AID in different onco-hematologic conditions. The l...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study assessed medical costs of early discontinuation of hypomethylating agents in patients with refractory anemia with excess blasts (RAEB) subgroup of MDS using SEER-Medicare linked database (2010-2016). Patients discontinuing HMAs before the recommended timeframe needed to elicit clinical response may experience suboptimal outcomes and incur higher healthcare costs pointing to the potential benefit of treatment continuity as per guidelines.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This study assessed medical costs of early discontinuation of hypomethylating agents (HMAs) in patients with refractory anemia with excess blasts subgroup of myelodysplastic syndromes using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database (2010-2016). Patients discontinuing HMAs before the recommended time frame required to elicit clinical response may experience suboptimal outcomes and incur higher healthcare costs, thus pointing to the potential benefit of treatment continuity as per guidelines.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This study assessed underuse of treatment with hypomethylating agents (HMAs) among newly diagnosed myelodysplastic syndromes (MDS) patients with refractory anemia with excess blasts (RAEB). Of 1,190 patients from the SEER-Medicare database, 526 (44%) did not use HMAs, 295 (25%) were non-persistent HMA users; while, 369 (31%) were persistent HMA users. Several clinical and demographic factors were associated with HMA underuse.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Conditions:   Myelodysplastic Syndromes;   Multiple Myeloma;   Anemia Intervention:   Drug: INCB000928 Sponsor:   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: ESA treatment for anemia is associated with lower blood glucose in hematologic patients. In those who also have diabetes mellitus, ESA might contribute to glucose control, and even to hypoglycemia. Glucose monitoring is thus advised. Further studies with both diabetic and nondiabetic patients are needed to clarify this association and underlying mechanisms.Acta Haematol
Source: Acta Haematologica - Category: Hematology Source Type: research
More News: Anemia | Myelodysplastic Syndrome | Myeloma | Research